The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing
- 15 January 2021
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10274), 630-640
- https://doi.org/10.1016/s0140-6736(20)32722-7
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970sBlood, 2013
- Integration Frequency and Intermolecular Recombination of rAAV Vectors in Non-human Primate Skeletal Muscle and LiverMolecular Therapy, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BThe New England Journal of Medicine, 2011
- Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in ChinaHaemophilia, 2010
- Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitorsJournal of Thrombosis and Haemostasis, 2007
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- European Study on Orthopaedic Status of haemophilia patients with inhibitorsHaemophilia, 2007
- The Hemophilias — From Royal Genes to Gene TherapyThe New England Journal of Medicine, 2001
- Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and BJournal of Internal Medicine, 1992